Brief Introduction

Medizone International, Inc.  (OTCBB: MZEI) is a research and development company engaged in developing AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools, clean rooms, hotels, cruise ships and other critical infrastructure. Hospital beta testing of the production prototype was conducted in October 2010. The trial results were deemed to be highly successful.

Annual Shareholder Meeting

• Medizone held its annual meeting of shareholders on August 26, 2009 in Reno, Nevada
• Directors were elected  -- Edwin G. Marshall, Richard G. Solomon, Daniel D. Hoyt, Dr. Michael E. Shannon
• For the first time since the company became a public company in 1986 the shareholders voted to increase the number of shares the company is authorized to issue
• A modest portion of the newly authorized shares were earmarked to facilitate the financing of the October 2010 hospital beta testing and initial production of the company's AsepticSure™ hospital sterilization system
• The availability of increased authorized capital has also provided management greater flexibility for strategic development

The Company is currently engaged in preparation for phase two HAI-centric hospital trials, having already embarked on a soft-launch of its AsepticSure technology to both the health care and veterinary markets.

Promising trials at Purdue University with respect to our bed bug initiative has increased the possibility that large scale field trials may be rolled out later in 2012.

Bio-terrorism countermeasures trials which began at the Level 4 Winnipeg National Microbiological Laboratory in November 2011 continue to be a work-in-progress and updates will be published when they become available.

Initial Sales of AsepticSure™

• Commencement of commercial deliveries began in April of 2012
• Medizone's target is to achieve profitability moving into the 4th quarter of 2012.

Partnership with Multinational Corporation

Following proof of reliability of the first commercially delivered units, Medizone will have optimized its strengths as a research and development company.  It then expects to partner with a large corporation embedded in the hospital  sector for increased:

• Manufacturing capacity
• Service capabilities
• National, regional and global sales